Breakthrough findings reported in 2018 provide the foundations for paradigm shifts in the care of patients with ovarian cancer. These results have implications for treatment in the first-line setting (with improved and refined use of established treatment modalities), firmly introduce concepts of consolidation and maintenance therapy, and enable more accurate prediction of drug sensitivity and resistance.
Advances in ovarian cancer treatment with interval surgery followed by hyperthermic intraperitoneal chemotherapy and re-definition of the value of secondary surgery pave the way to improve outcomes using established therapies2,3.
Findings from the SOLO1 trial demonstrated a substantial improvement in progression-free survival in women with BRCA1/2 mutations using maintenance olaparib following initial platinum-based chemotherapy5.
Translational findings demonstrated the importance of testing tissues before therapy, potentially including identification of copy number variation signatures or BRCA1 methlyation, which might improve the integration of predictive biomarkers for ovarian cancer therapy8,9.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Bommert, M. et al. When should surgery be used for recurrent ovarian carcinoma? Clin. Oncol. 30, 493–497 (2018).
Coleman, R. L. et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology/Gynecologic Oncology Group (GOG) study [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 5501 (2018).
van Driel, W. J. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 378, 230–240 (2018).
Fotopoulou, C. et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann. Oncol. 29, 1610–1613 (2018).
Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1810858 (2018).
Mirza, M. R., Pignata, S. & Ledermann, J. A. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann. Oncol. 29, 1366–1376 (2018).
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262–1270 (2018).
Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9, 3970 (2018).
Lin, K. K. et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-0715 (2018).
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Oza, A.M. Advances in prediction for ovarian cancer treatment stratification. Nat Rev Clin Oncol 16, 75–76 (2019). https://doi.org/10.1038/s41571-018-0147-3
This article is cited by
Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer
Journal of Shanghai Jiaotong University (Science) (2021)